Business: Ironwood Pharmaceuticals is focused on creating medicines that make a difference for patients, building value to earn the continued support of their fellow shareholders, and empowering their team to passionately pursue excellence. They discovered, developed and are commercializing linaclotide, which is approved in the United States and a number of other countries. Their pipeline priorities include exploring further opportunities for linaclotide, as well as leveraging their therapeutic expertise in gastrointestinal disorders and their pharmacologic expertise in guanylate cyclases to address patient needs across the upper and lower gastrointestinal tract. Ironwood was founded in 1998 and is headquartered in Cambridge, Mass. LINZESS and CONSTELLA are trademarks owned by Ironwood Pharmaceuticals, Inc.